Xenetic Biosciences Inc
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, pancreatic ductal adenocarcinoma, colorectal carcinoma, a… Read more
Xenetic Biosciences Inc (XBIO) - Total Liabilities
Latest total liabilities as of September 2025: $1.11 Million USD
Based on the latest financial reports, Xenetic Biosciences Inc (XBIO) has total liabilities worth $1.11 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Xenetic Biosciences Inc - Total Liabilities Trend (2011–2024)
This chart illustrates how Xenetic Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Xenetic Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Xenetic Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
QPR Software Oyj
HE:QPR1V
|
Finland | €3.10 Million |
|
Wilhelmina
OTCQX:WHLM
|
USA | $16.35 Million |
|
Connected Minerals Ltd
AU:CML
|
Australia | AU$110.87K |
|
STS Group AG
XETRA:SF3
|
Germany | €177.70 Million |
|
Emdeki Utama Tbk PT
JK:MDKI
|
Indonesia | Rp73.09 Billion |
|
KD Corporation
KQ:044180
|
Korea | ₩277.57 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Xenetic Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Xenetic Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Xenetic Biosciences Inc (2011–2024)
The table below shows the annual total liabilities of Xenetic Biosciences Inc from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $894.26K | +10.46% |
| 2023-12-31 | $809.59K | -24.56% |
| 2022-12-31 | $1.07 Million | -24.48% |
| 2021-12-31 | $1.42 Million | +47.42% |
| 2020-12-31 | $963.97K | -77.76% |
| 2019-12-31 | $4.33 Million | -4.09% |
| 2018-12-31 | $4.52 Million | -7.07% |
| 2017-12-31 | $4.86 Million | +1.20% |
| 2016-12-31 | $4.80 Million | -53.35% |
| 2015-12-31 | $10.30 Million | +76.50% |
| 2014-12-31 | $5.84 Million | -14.79% |
| 2013-12-31 | $6.85 Million | +49.11% |
| 2012-12-31 | $4.59 Million | +1980.58% |
| 2011-12-31 | $220.74K | -- |